The FINER trial is a randomized, double‐blind, phase III study using ipatasertib plus fulvestrant versus placebo plus fulvestrant in ER+/HER2− BC with 250 patients who progressed after first‐line CDK4/6 inhibitor and AI therapy [371]. Here, ESR1 is linked to breast cancer.